Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat the highly contagious stomach virus.

CEO Larry Ellison’s claims that artificial intelligence (AI) could help develop messenger RNA-based (mRNA) vaccines to cure ...

Only 23 countries use climate data for health surveillance, says head of WMO, adding more collaboration needed ...

Moderna is testing a norovirus vaccine in a phase three trial. Results could be available as soon as this year.

Plus: Moderna’s bird flu vaccine, Obamacare enrollment breaks records, and AstraZeneca’s new breast cancer treatment is FDA ...

To get a sense of who is truly in control of Moderna, Inc. ( NASDAQ:MRNA ), it is important to understand the ownership structure of the business. With 69% stake, institutions possess the maximum ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...

We recently compiled a list of the Jim Cramer Recently Discussed These 17 Stocks And Chinese Hackers. In this article, we are ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.